11. Use of the construct according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of B-cell lymphoma.

12. Use of the construct according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of multiple myeloma.

13. Use of the construct according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of non-Hodgkin's lymphoma.

14. Use of the construct according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of chronic myelogenous leukemia.

15. Use of the construct according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of chronic lymphocytic leukemia.

16. Use of the construct according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment of or acute myelogenous leukemia.